Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Perrone

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Circulation|November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced TrialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|October 1, 2025
Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registryWan Ting Tay, Tiew-Hwa Katherine Teng, Wouter Ouwerkerk, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Circulation. Heart Failure|July 8, 2018
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Martin P Lefkowitz, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Circulation|November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced TrialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|October 1, 2025
Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registryWan Ting Tay, Tiew-Hwa Katherine Teng, Wouter Ouwerkerk, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Circulation. Heart Failure|July 8, 2018
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Martin P Lefkowitz, et al.
Pageof 8